WAY-470

{{Short description|Chemical compound}}

{{drugbox

| drug_name = WAY-470

| image = WAY-470_structure.png

| image_class = skin-invert-image

| C = 17 | H = 22 | N = 2

| IUPAC_name = 1,16-diazatetracyclo[8.8.1.0^2,9.0^14,19]nonadeca-2(9),10,12,14(19)-tetraene

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 422318-22-7

| ChemSpiderID = 8213527

| PubChem = 10037962

| ChEMBL = 89738

| UNII =

| smiles = C1CCCC2=C(CC1)C3=CC=CC4=C3N2CCNC4

| StdInChI = 1S/C17H22N2/c1-2-4-9-16-14(7-3-1)15-8-5-6-13-12-18-10-11-19(16)17(13)15/h5-6,8,18H,1-4,7,9-12H2

| StdInChIKey = FEOKYCHGJRHIDE-UHFFFAOYSA-N

}}

WAY-470 is a drug which acts as an agonist at 5-HT_2A and 5-HT_2C receptors though with lower affinity at 5-HT_2B. It has similar binding affinity to 5-HT_2A and 5-HT_2C but shows functional selectivity for 5-HT_2C.{{cite journal | vauthors = Sabb AL, Vogel RL, Welmaker GS, Sabalski JE, Coupet J, Dunlop J, Rosenzweig-Lipson S, Harrison B | display-authors = 6 | title = Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor | journal = Bioorganic & Medicinal Chemistry Letters | volume = 14 | issue = 10 | pages = 2603–2607 | date = May 2004 | doi = 10.1016/j.bmcl.2004.02.100 | pmid = 15109661 }}{{cite journal | vauthors = Lee J, Jung ME, Lee J | title = 5-HT2C receptor modulators: a patent survey | journal = Expert Opinion on Therapeutic Patents | volume = 20 | issue = 11 | pages = 1429–1455 | date = November 2010 | doi = 10.1517/13543776.2010.518956 | pmid = 20849206 | s2cid = 32729624 }}